[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647055":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":17,"centralContacts":18,"locations":24,"responsibleParty":59,"collaborators":17,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":17,"enrollmentInfo":70,"targetDuration":17,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":17,"overallStatus":81,"whyStopped":17,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nice","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"recessive dystrophic epidermolysis bullosa with dysphagia treated with oral BUDESONIDE","The retrospective data collected will be entered into an eCRF and then analyzed centrally",[12],"Other: The retrospective data collected will be entered into an eCRF and then analyzed centrally",[14],{"type":6,"name":10,"description":15,"armGroupLabels":16,"otherNames":17},"there is no treatment for the study but the patient take a treatment out of MMA and the retrospectives datas collected will be entered into an eCRF and then analyzed centrally by the sponsor",[9],null,[19],{"name":20,"role":21,"phone":22,"phoneExt":17,"email":23},"Christine CHIAVERINI, Doctor","CONTACT","0492034702","chiaverini.c@chu-nice.fr",[25,37,50],{"facility":26,"status":17,"city":27,"state":28,"zip":29,"country":28,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":17},"CHU de Nice","Nice","France","06000","FR",{"type":32,"coordinates":33},"Point",[34,35],7.26608,43.70313,{"lat":35,"lon":34},{"facility":38,"status":17,"city":39,"state":28,"zip":40,"country":28,"countryCode":30,"cosmosGeoPoint":41,"geoPoint":45,"contacts":46},"APHP Necker","Paris","75000",{"type":32,"coordinates":42},[43,44],2.3488,48.85341,{"lat":44,"lon":43},[47],{"name":48,"role":21,"phone":22,"phoneExt":17,"email":49},"Nathalia BELLON, Doctor","nathalia.bellon@aphp.fr",{"facility":51,"status":17,"city":39,"state":28,"zip":40,"country":28,"countryCode":30,"cosmosGeoPoint":52,"geoPoint":54,"contacts":55},"APHP St Louis",{"type":32,"coordinates":53},[43,44],{"lat":44,"lon":43},[56],{"name":57,"role":21,"phone":22,"phoneExt":17,"email":58},"Pauline Bataille, Doctor","pauline.bataille@aphp.fr",{"type":60,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100647055","treatment-of-dysphagia-in-patients-with-dystrophic-epidermolysis-bullosa-with-budesonide-a-retrospective-bicentric-study-nice---paris-st-louis--necker-ebude-study-100647055",false,"NCT07684105","Treatment of Dysphagia in Patients With Dystrophic Epidermolysis Bullosa With Budesonide: a Retrospective Bicentric Study Nice - Paris St Louis \u002F Necker (EBUDE Study)","EBUDE","Inclusion Criteria:\n\nPatients of both sexes, of any age, with EBD in dominant or recessive form, treated for at least one month with budesonide for dysphagia resistant to usual treatments.\n\nA description of the clinical form must be available in the file. The patient must assess the benefit of treatment at 1 and\u002For 3 months of Budesonide.\n\nPatients must be affiliated with social security. For adults, consent of non-opposition is required, and for minors, non-opposition from one of the parents or the person holding parental authority must be collected.\n\nExclusion Criteria:\n\nNo precise clinical or biological diagnosis. Treatment with Budesonide \\\u003C 1 month. No evaluation criteria in the file \u002F Objection to the use of data (withdrawal of non-opposition)","ALL","1 Year",{"count":71,"type":72},15,"ESTIMATED","INTERVENTIONAL",[75],"NA","Budesonide is an anti-inflammatory medication that works by decreasing the immune system's overreaction. In the treatment of eosinophilic esophagitis, especially with Jorveza or a preparation made in a pharmacy, it reduces the production of substances responsible for inflammation in the esophagus. This action reduces the accumulation of certain inflammatory cells (eosinophils) and thus improves the symptoms and lesions of the esophagus.\n\nDystrophic epidermolysis bullosa (EBD) is a rare genetic disease that makes the skin and mucous membranes very fragile. Blisters, sores and wounds can appear as a result of even minor trauma. Scarring is often abnormal and can cause tissue to shrink or shrink.\n\nTo date, only two studies involving a total of eight children with EBD have evaluated a budesonide-based preparation. The results show an improvement in swallowing difficulties (dysphagia) as well as good tolerance of the treatment. However, there are currently no published data regarding the use of Jorveza in the form of an orally disintegrating tablet in adults with EBD.\n\nThrough the follow-up of patients treated at the MAGEC reference center, specialized in rare genetic diseases of the skin and mucous membranes, we aim to evaluate the interest and effects of budesonide treatment in individuals with EBD presenting with dysphagia.",[78,79,80],"Recessive Dystrophic Epidermolysis Bullosa","Dysphagia","Esophageal Stenosis","NOT_YET_RECRUITING","2026-07-01",{"date":84,"type":85},"2026-07-06","ACTUAL",{"date":82,"type":72},{"date":88,"type":72},"2027-06-30",{"name":5,"class":6},3]